Business Context and Reporting Period
This Form 8-K is a current report filed by Ra Medical Systems, Inc. (the "Company") on October 17, 2022. The filing primarily addresses the completion of an at-the-market (ATM) equity facility and provides updates regarding the proposed reverse merger with Catheter Precision, Inc. ("Catheter"), a privately held medical device company focused on cardiac electrophysiology.
Key Financial Metrics
- Capital Raised: The Company completed its ATM facility, raising gross proceeds of $7.6 million.
- Revenue and Profit: This filing does not contain specific revenue, profit, or cash flow figures for the reporting period. It references prior filings (Form 10-Q for the period ended June 30, 2022, and Form 8-K filed September 12, 2022) for audited and unaudited financial statements of Catheter Precision and pro forma combined financial information.
- Debt and Liquidity: Specific debt levels and liquidity ratios are not disclosed in this text. The filing notes that the Merger Agreement includes a closing condition regarding a minimum "Net Cash" amount at closing.
Material Changes and Transaction Status
The primary material event is the completion of the ATM facility, which provides immediate liquidity. Additionally, the filing reiterates the status of the Merger Agreement entered into on September 12, 2022:
- Transaction Type: Stock-for-stock reverse merger where Catheter becomes a wholly-owned subsidiary of Ra Medical.
- Expected Closing: The Merger is expected to close before the end of 2022, subject to conditions.
- Conditions Precedent: Closing is subject to shareholder approval from both companies, satisfaction of closing conditions, and potentially a minimum prevailing stock price for Ra Medical.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The combined company intends to focus on the cardiac electrophysiology market. Management has issued forward-looking statements regarding the expected timing of the Merger and future access to capital markets.
Risks and Contingencies:
- Merger Completion: Risks include the failure to satisfy closing conditions, potential delays, or the inability to achieve anticipated benefits.
- Stock Price Sensitivity: If Ra Medical's stock price drops below certain levels, the merger consideration received by Catheter stockholders will be adversely impacted. The parties reserve the right to waive conditions or revise the agreement.
- Regulatory and Listing: Risks related to SEC "shell company" rules and the ability to maintain listing on the NYSE American.
- Market Conditions: Ongoing volatility in stock markets and the economic impact of the COVID-19 pandemic.
Investor Verification Checklist
- Verify the Definitive Proxy Statement and Private Placement Memorandum/Joint Information Statement for detailed terms of the Merger and voting procedures.
- Review the Form 8-K filed on September 12, 2022 for Catheter Precision's audited financial statements (ended Dec 31, 2021) and unaudited statements (ended June 30, 2022).
- Examine the unaudited pro forma combined financial information filed as Exhibit 99.6 to the September 12, 2022 Form 8-K to understand the projected financial position of the combined entity.
- Monitor Ra Medical's stock price relative to the minimum prevailing stock price condition required for the Merger to close.
- Confirm the status of shareholder approvals required from both Ra Medical and Catheter Precision stockholders.